Developer of a mental and behavioural health platform designed to increase mental health consultancy and therapy accessi
Developer of a mental and behavioural health platform designed to increase mental health consultancy and therapy accessibility.
Leisure Facilities📍 Greensboro, NC
Current Valuation
$1.6B
as of 2021-Q2
UNICORN
QL Price
$1.9B
+16% vs last round
QuantLogix's current estimate for SonderMind, published 2026-09-27 — above the last disclosed round of $1.6B (2021-Q2).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$1.6B
2021-Q2
weight 0.03
Secondary market print
$1.9B
2026-06-27
weight 0.58
How this price has held up
No round has priced for SonderMind since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, SonderMind, 2026-09-27 (16255498aaa70001).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is SonderMind going public?
No. SonderMind is private and has not filed to go public. There is no S-1 on file.
What is SonderMind's valuation in 2026?
SonderMind is valued at $1.6B as of 2021-Q2, set by its Series C ($241.55M, May 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has SonderMind filed an S-1?
No public S-1 is on file for SonderMind.
How much has SonderMind raised?
SonderMind has raised $275.05M in total, most recently a Series C of $241.55M in May 2021.
Is SonderMind publicly traded — can you buy SonderMind stock?
No. SonderMind is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for SonderMind on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
HQ
Greensboro, NC
Total Raised
$275.05M
Last Round
Series C — $241.55M (May 2021)
IPO Status
private
Fundraising Status
Series C · $241.55M · 5y 4mo ago
privateTotal raised $275.05M
Secondary Market
Implied price / share
$21
Last round price / share
$18.03
vs last round
+16.5%
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C
$241.55M
May 2021
—
$1.6B
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for SonderMind — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-27. Re-checked weekly.
Talent Signal
Hiring trend
▶ Hiring steady
-4% vs 2026-08
Open roles
133
via ashby
Product-build share
74%
engineering, research, product, design
Trajectory
steady
heavy product build — 74% of open roles are product-building functions (engineering/research/product) — 98 of 133 open roles are medical.
Counted from SonderMind's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Health CareTherapeuticsWellnessmHealth
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q2. Refreshed quarterly.